EVOTEC SEINH O.N. overview

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English. Webcast details Date: Wednesday, 06...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec SE to announce results for the first nine months 2024 on 06 November 2024 30.10.2024 / 08:10 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 30 October 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call...

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Bristol Myers Squibb expand proteomics partnership 23.10.2024 / 07:29 CET/CEST The issuer is solely responsible for the content of this announcement. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value Hamburg, Germany, 23 October 2024:...

Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies 26.09.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies Hamburg, Germany, 26 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT,...

J.POD ® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just - Evotec Biologics' J.POD ® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions HAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 20, 2024 / Just - Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO), today...

EQS-News: Evotec SE / Key word(s): Miscellaneous Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU) 20.09.2024 / 15:29 CET/CEST The issuer is solely responsible for the content of this announcement. J.POD ® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region Just – Evotec Biologics’ J.POD ® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical...